Cutaneous small-vessel vasculitis;La vasculite cutanea dei piccoli vasi

Giornale Italiano di Dermatologia e Venereologia

Volumn 139, Issue 5, 2004, Pages 389-413

  Ghersetich, I ^a   Buggiani, G ^a   Brazzini, B ^a   Lotti, T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Blood vessels; Skin; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; ANTIHISTAMINIC AGENT; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEFIBROTIDE; ETHYLESTRENOL; FIBRINOLYTIC AGENT; HEAT SHOCK PROTEIN; HEPARIN; IMMUNOSUPPRESSIVE AGENT; INDOMETACIN; INTERCELLULAR ADHESION MOLECULE 1; MESOGLYCAN; METHOTREXATE; MONOCLONAL ANTIBODY; NEUROKININ A; NEUROPEPTIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENFORMIN; PHENYLBUTAZONE; POTASSIUM IODIDE; STANOZOLOL; SUBSTANCE P; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CHRONIC DISEASE; COMPLEMENT ACTIVATION; CUTANEOUS SMALL VESSEL VASCULITIS; ENDOTHELIUM CELL; FIBRINOLYSIS; HISTOPATHOLOGY; HUMAN; IDIOPATHIC DISEASE; IMMUNE RESPONSE; MONONUCLEAR CELL; PATHOGENESIS; PURPURA; REVIEW; SKIN BLOOD VESSEL DISORDER; SMALL VESSEL VASCULITIS; T LYMPHOCYTE ACTIVATION;

EID: 10844249273     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Stone JH, Calabrese LH, Hoffmann GS, Pusey CD, Hunder GG, Hellmann DB. Vasculitis. A collection of pearls and myths. Rheum Dis Clin North Am 2001;27:677-728.
2. Gibson LE. Cutaneous vasculitis update. Dermatol Clin 2001;19:603-18.
3. Hautmann G, Campanile G, Lotti TM. The many faces of cutaneous vasculitis. Clin Dermatol 1999;17:515-31.
4. Lotti T, Ghersetich I, Comacchi C, Iorizzo JL. Cutaneous small-vessel vasculitis. J Am Acad Dermatol 1998;39:667-87; quiz 688-90.
5. Stegeman CA, Kallenberg CG. Clinical aspects of primary vasculitis. Springer Semin Immunopathol 2001;23:231-51.
6. Lotti TM, Comacchi C, Ghersetich I. Cutaneous necrotizing vasculitis. Int J Dermatol 1996;35:457-74.
7. Gilliam JN, Smiley JD. Cutaneous necrotizing vasculitis and related disorders. Ann Allergy Asthma Immunol 1976;37:328-39.
8. Fauci AS, Haynes B, Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med 1978:89:660-76.
9. Callen JP. Cutaneous vasculitis: what have we learned in the past 20 years? Arch Dermatol 1998;134:355-7.
10. Vidaller A, Sais G. Cutaneous leukocytoclastic vasculitis: the dynamic nature of the infiltrate and the expression of adhesion molecules. J Cutan Pathol 2001;28:327-8.
11. Jessop SJ. Cutaneous leukocytoclastic vasculitis: A clinical and aetiological study. Br J Rheumatol 1995;34:942-5.
12. Comacchi C, Ghersetich I, Lotti T. La vasculite necrotizzante cutanea. G Ital Dermatol Venereol 1998;133:23-49.
13. Campanile G, Lotti T. Clinical aspects of cutaneous necrotizing vasculitis. Int Angiol 1995;14:151-61.
14. Callen JP. Are Henoch-Schönlein purpura and hypersensitivity vasculitis in adults truly distinct entities? A dermatologist's perspective. Clin Exp Rheumatol 2000;18:659-60.
15. Saulsbury FT. Henoch-Schönlein purpura in children. Report of 100 patients and review of the literature. Medicine (Baltimore) 1999;78:395-409.
16. Wyatt RJ, Hogg RJ. Evidence-based assesment of treatment options for children with IgA nephropaties. Pediatr Nephrol 2001;16:156-67.
17. Jennette CJ, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997;337:1512-23.
18. Saraclar Y, Tinaztepe K, Adaliaglu G, Tuncer A. Acute hemorrhagic edema of infancy: a variant of Henoch-Schönlein purpura or a distinct clinical entity? J Allergy Clin Immunol 1990;86 (4 Pt 1):473-83.
19. Campanile G, Hautmann G, Lotti T. The etiology of cutaneous necrotizing vasculitis. Clin Dermatol 1999;17:505-8.
20. Jorizzo JL. Classification of vasculitis. J Invest Dermatol 1993;100 Suppl: 106S-110S.
21. Zeek P. Periarteritis nodosa: a critical review. Am J Clin Pathol 1952;22:777-90.
22. Copeman PWM, Ryan TJ. The problems of classification of cutaneous angiitis with reference to histopathology and pathogenesis. Br J Dermatol 1970;82 Suppl 5:2-14.
23. Ghersetich I, Comacchi C, Jorizzo JL, Katsambas A, Lotti TM. Proposal for a working classification of cutaneous vasculitis. Clin Dermatol 1999;17:499-503.
24. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
25. Rao JK, Allen NB, Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 1998;129:345-52.
26. Calabrese LH. Sorting out cutaneous vasculitis - a rheumatologist's perspective. Clin Exp Rheumatol 2000;18:661-3.
27. Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 1990;33:1065-7.
28. Ghersetich I, Jorizzo JL, Lotti T. Working classification of vasculitis. Int Angiol 1995;14:101-6.
29. Sneller MC, Fauci AS. Pathogenesis of vasculitis syndromes. Med Clin North Am 1997;81:221-42.
30. Kevil CG, Bullard DC. Roles of leukocyte/endothelial cell adhesion molecules in the pathogenesis of vasculitis. Am J Med 1999;106:677-87.
31. Fortin PR. Vasculitides associated with malignancy. Curr Opin Rheumatol 1996;8:30-3.
32. Kurzrock R, Cohen PR, Markowitz A. Clinical manifestations of vasculitis in patients with solid tumors. A case report and review of the literature. Arch Intern Med 1994;154:334-40.
33. Swerlick RA, Lawley TJ. Cutaneous vasculitis: its relationship to systemic disease. Med Clin North Am 1989;73:1221-35.
34. Ramos-Casals M, Cervera R, Yague J, Garcia-Carrasco M, Trejo O, Jimenez S et al. Cryoglobulinemia in primary Sjogren's syndrome: prevalence and clinical characteristics in a series of 115 patients. Semin Arthritis Rheum 1998;28:200-5.
35. Davis MD, Daoud MS, McEvoy MT, Su WP. Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol 1997;37:199-203.
36. Langford CA. Treatment of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: where do we stand? Arthritis Rheum 2001;44:508-12.
37. Danning CL, Illei GG, Boumpas DT. Vasculitis associated with primary rheumatologic diseases. Curr Opin Rheumatol 1998;10:58-65.
38. Voskuyl A, Zwinderman A, Westedt M, Vandenbroucke J, Breedveld F, Hazes J. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis 1996;55:190-2.
39. Kerr G, Hoffman G. Systemic lupus erythematosus and the cardiovascular system: vasculitis. In: Lahita R editor. Systemic lupus erythematosus. 2nd ed. New York: Churchill Livingstone; 1992.p. 719-29.
40. Yamamoto T, Yokoyama A. Hypergammaglobulinemic purpura associated with Sjogren syndrome and cronic C type hepatitis. J Dermatol 1997;24:7-11.
41. Jorizzo J. Behçet's disease: an update based on the 1985 international conference in London. Arch Dermatol 1986;122:556-8.
42. Gyselbrecht L, DeKeyser F, Ongenae K, Naeyaert J, Praet M, Veys E. Etiological factors and underlying conditions in patients with leukocytoclastic vasculitis. Clin Exp Rheumatol 1996;14:665-8.
43. Dupin N, Chosidow O, Lunel F, Cacoub P, Musset L, Cresta P et al. Essential mixed cryoglobulinemia. A comparative study od dermatologic manifestations in patients infected or noninfected with hepatitis C virus. Arch Dermatol 1995;131:1124-7.
44. Cresta P, Musset L, Cacoub P, Frangeul L, Vitour D, Poynard T et al. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 1999;45:122-8.
45. Cohen P, Roulot D, Ferriere F, Nguyen QT, Lortholary O, Jarrousse B et al. Prevalence of cryoglobulins and hepatitis C virus infection in HIV-infected patients. Clin Exp Rheumatol 1997;15:523-7.
46. Dimitrakopoulos AN, Kordossis T, Hatzakis A, Moutsopoulos HM. Mixed cryoglobulinemia in HIV-1 infection: the role of HIV-1. Ann Intern Med 1999;130:226-30.
47. Kapur N, Tympanidis P, Colville C, Yu RC. Long-term follow-up of a patient with cutaneous vasculitis secondary to mixed cryoglobulinaemia and hepatitis C virus. Clin Exp Dermatol 2002;27:37-9.
48. Ghersetich I, Comacchi C, Katsambas A, Lotti T. Cellular steps in pathogenesis of cutaneous necrotizing vasculitis. Clin Dermatol 1999;17:597-601.
49. Panconesi E, Lotti T. Fibrinolysis and fibrinolytic drugs. In: Greaves MW, Schuster S editors. Handbook of experimental pharmacology. Berlin: Springer-Verlag; 1989. p. 279-300.
50. Merkel PA. Drug-induced vasculitis. Rheum Dis Clin North Am 2001;27:849-62.
51. Haber M, Marboe C, Fenoglio J. Vasculitis in drug reactions and serum sickness. In: Churg A, Churg J editors. Systemic vasculitides. New York: Igaku-Shoin; 1991. p. 305.
52. Somer T, Finegold SM. Vasculitides associated with infections, immunization, and antimicrobial drugs. Clin Infect Dis 1995;20:1010-36.
53. Teofoli P, Lotti TM. Cytokines, fibrinolysis and vasculitis. Int Angiol 1995;14:125-9.
54. Trejo O, Ramos-Casals M, Garcia-Carrasco M, Yague J, Jimenez S, de la Red G et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine 2001;80:252-62.
55. Dispenzieri A, Gorevic PD. Cryoglobulinemia. Hematol Oncol Clin North Am 1999;13:1315-49.
56. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-88.
57. Ramos-Casals M, Trejo O, Garcia-Carrasco M, Cervera R, Font J. Mixed cryoglobulinemia: new concepts. Lupus 2000;9:83-91.
58. Lamprecht P, Gause A, Gross WL. Cryoglobulinemic vasculitis. Arthritis Rheum 1999;42:2507-16.
59. Cohen SJ, Pittelkow MR, Su WP. Cutaneous manifestations of cryoglobulinemia: clinical and histopathologic study of 72 patients. J Am Acad Dermatol 1991;25:21-7.
60. Misiani R, Bellavita P, Fenili D, Borelli G, Marchesi D, Massazza M et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992;117:573-7.
61. Weimer CE Jr, Sahn EE. Follicular accentuation of leukocytoclastic vasculitis in an HIV-seropositive man: report of a case and review of the literature. J Am Acad Dermatol 1991;24:898-902.
62. Black AK. Urticarial vasculitis. Clin Dermatol 1999;17:565-9.
63. Wisnieski JJ. Urticarial vasculitis. Curr Opin Rheumatol 2000;12:24-31.
64. Borradori L, Rybojad M, Puissant A, Dallot A, Verola O, Morel P. Urticarial vasculitis associated with a monoclonal IgM gammopathy: Schnitzler's syndrome. Br J Dermatol 1990;123:113-8.
65. Grassegger A, Greil R, Feichtinger J, Fritsch P, Hintner H. Urticarial vasculitis as a symptom of Muckle-Wells syndrome? Hauthartz 1991;42:116-9.
66. LeBoit PE, Yen TSB, Wintroub B. The evolution of lesions in erythema elevatum diutinum. Am J Dermatopathol 1986;8:392-402.
67. McCalmont CS, McCalmont TH, Jorizzo JL, White WL, Leshin B, Rothberger H. Livedo vasculitis: vasculitis or thrombotic vasculopathy? Clin Exp Dermatol 1992;17:4-8.
68. Marsch WC, Mucklemann R. Generalized racemose livedo with cerebrovascular lesions (Sneddon syndrome): an occlusive arteriolopathy due to proliferation and migration of medial smooth muscle cells. Br J Dermatol 1985;112:703-8.
69. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Garcia-Fuentes M. Cutaneous vasculitis in children and adults. Associated diseases and etiologic factors in 303 patients. Medicine (Baltimore) 1998;77:403-18.
70. Bliel L, Manger B, Winkler TH. The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrandt factor antigen, and fibronectin for the diagnosis of systemic vasculitis. J Rheumatol 1991;18:1199-206.
71. Harper L, Savage CO. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol 2000;190:349-59.
72. Savige J, Davies D, Falk RJ, Jennette JC, Wiik A. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int 2000;57:846-62.
73. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998;41:1521-37.
74. Bajema IM, Hagen EC. Evolving concepts about the role of antineutrophil cytoplasmic antoantibodies in systemic vasculitides. Curr Opin Rheumatol 1999;11:34-40.
75. Franssen CF, Stegeman CA, Kallenberg CG, Gans RO, De Jong PE, Hoorntje SJ et al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int 2000;57:2195-206.
76. Choi HK, Liu S, Merkel PA, Coldtiz GA, Niles JL. Diagnostic performance of antineutrophil cytoplasmic antibodies test for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. J Rheumatol 2001;28:1584-90.
77. Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ et al. International Consensus Statement on Testin and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999;111:507-13.
78. Jayne D, Gaskin G, Pusey C, Lockwood C. ANCA and predicting relapse in systemic vasculitis. QJM 1995;88:127-33.
79. Lotti T, Ghersetich I, Comacchi C, Katsambas A, Tsoureli E. Langerhans' cells and cutaneous necrotizing vasculitis. Clin Dermatol 1999;17:591-6.
80. Ghersetich I, Campanile G, Comacchi C, Lotti T. The cell-mediated pathway in the pathogenesis of the leukocytoclastic form of cutaneous necrotizing vasculitis. "Dermatology 2000", 1993, May 18-21, Vienna, Austria.
81. Lotti T, Ghersetich I, Comacchi C, Panconesi E. Purpuras and related conditions. J Eur Acad Dermatol Venereol 1996;7:1-25.
82. Bianchi B, Katsambas A, Lotti T. Neuropeptides and endothelial injury in cutaneous vasculitis. Clin Dermatol 1999;17:625-7.
83. Lotti T, Benci M, Sarti MG. Psychogenic purpura with abnormally increased tPA dependent cutaneous fibrinolytic activity. Int J Dermatol 1993;32:521-3.
84. Hautmann G, Lotti T. The possible role of regulatory peptides in the pathogenesis of cutaneous necrotizing vasculitis. Int Angiol 1995;14:138-50.
85. Emmi L. Sindrome da anticorpi antifosfolipidi. In: Romagnani S, Emmi L, Almerigogna F editors. Malattie del sistema immunitario. 2nd ed. Milano: McGraw-Hill; 2000. p.362-72.
86. Ghersetich I, Lotti T, Campanile G, Comacchi C, Bacci S, Romagnoli P. Lymphocytes and accessory cells in the infiltrate of leukocytoclastic vasculitis. "SCUR Meet", 1992, September 17-19, Lyon, France.
87. Hautmann G, TM Lotti. The fibrinolytic system and the skin. Life Chem Rep 1996;14:97-107.
88. Comacchi C, Ghersetich I, Katsambas A, Lotti T. γ/δ T lymphocytes and infection: pathogenesis of leukocytoclastic cutaneous necrotizing vasculitis. Clin Dermatol 1999;17:603-7.
89. Comacchi C, Ghersetich I, Lotti T. Una cellula emergente in dermatologia: il linfocita T gamma/delta. G Ital Dermatol Venereol 1993;128:133-40.
90. Campanile G, Comacchi C, Ghersetich I, Lotti T. Gamma/delta TCR lymphocytes in cutaneous necrotizing vasculitis. Int Angiol 1995;14:119-24.
91. Campanile G, Comacchi C, Ghersetich I, Lotti T. Gamma/delta TCR lymphocytes in cutaneous necrotizing vasculitis (CNV): a clue to the infective etiology. J Invest Dermatol 1993;100:465.
92. Callen JP. A clinical approach to the vasculitis patient in the dermatologic office. Clin Dermatol 1999;17:549-53.
93. Allen NB, Bressler PB. Diagnosis and treatment of the systemic and cutaneous necrotizing vasculitis syndromes. Med Clin North Am 1997;81:243-59.
94. Sais G, Vidaller A, Jucgla A, Gallardo F, Peyri J. Colchicine in the treatment of cutaneous leukocytoclastic vasculitis. Results of a prospective, randomized controlled trial. Arch Dermatol 1995;131:1399-402.
95. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis. Arch Dermatol 1991;127:515-22.
96. Heurkens AH, Westedt ML, Breedveld FC. Prednisone plus azathioprine treatment in patients with reumatoid arthritis complicated by vasculitis. Arch Intern Med 1991;151:2249-54.
97. Vena GA, Cassano N. Immunosuppressive therapy in cutaneous vasculitis. Clin Dermatol 1999;17:633-40.
98. Gibson L. Cutaneous vasculitis. In: Rakel R, Bope E editors. Conn's current therapy 2001. Philadelphia: Saunders; 2001. p. 819-22.